

Amendments to the Claims:

Please substitute the following amended claims for the pending claims (based on the Article 34 amendment) with the same numbers in the above-identified application. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method selected from the following group:
 - (i) a method of inhibiting the oligomerization of procaspase-1, comprising inhibiting the binding of NOD2 to procaspase-1,
 - (ii) a method of inhibiting the activation of procaspase-1, comprising inhibiting the binding of NOD2 to procaspase-1, and
 - (iii) a method of inhibiting the production of caspase-1, comprising inhibiting the binding of NOD2 to procaspase-1.
2. (Original) A method of preventing and/or treating an inflammatory disease, comprising inhibiting the binding of NOD2 to procaspase-1.
3. (Original) A method of preventing and/or treating an inflammatory disease, comprising using at least one compound that inhibits the binding of NOD2 to procaspase-1.
4. (Currently amended) The method of preventing and/or treating an inflammatory disease according to claim 2 ~~or claim 3~~, wherein the inflammatory disease is sepsis, inflammatory bowel disease, Crohn's disease or rheumatic disorder.
5. (Original) A method of identifying a compound that inhibits the binding of NOD2 to procaspase-1, comprising contacting NOD2 and/or procaspase-1 with a compound under conditions that allow for the binding of NOD2 to procaspase-1, employing a system using a signal and/or marker capable of the detecting the binding of NOD2 to procaspase-1; and

detecting the presence or absence and/or change of the signal and/or marker to determine whether the compound inhibits the binding of NOD2 to procaspase-1.

6. (Original) An agent selected from the following group:

- (i) an agent for inhibiting the oligomerization of procaspase-1, which inhibits the binding of NOD2 to procaspase-1,
- (ii) an agent for inhibiting the activation of procaspase-1, which inhibits the binding of NOD2 to procaspase-1, and
- (iii) an agent for inhibiting the production of caspase-1, which inhibits the binding of NOD2 to procaspase-1.

7. (Original) An agent selected from the following group:

- (i) an agent for inhibiting the oligomerization of procaspase-1, comprising at least one compound that inhibits the binding of NOD2 to procaspase-1,
- (ii) an agent for inhibiting the activation of procaspase-1, comprising at least one compound that inhibits the binding of NOD2 to procaspase-1, and
- (iii) an agent for inhibiting the production of caspase-1, comprising at least one compound that inhibits the binding of NOD2 to procaspase-1.

8. (Original) An agent for preventing and/or treating an inflammatory disease, which inhibits the binding of NOD2 to procaspase-1.

9. (Original) An agent for preventing and/or treating an inflammatory disease, comprising at least one compound that inhibits the binding of NOD2 to procaspase-1.

10. (Currently amended) An agent for preventing and/or treating an inflammatory disease, comprising the agent according to claim 6 ~~or claim 7~~.

11. (Currently amended) The agent for preventing and/or treating an inflammatory disease

according to ~~claims~~ claim 8 ~~or~~ 9, wherein the inflammatory disease is sepsis, inflammatory bowel disease, Crohn's disease or rheumatic disorder.

12. (Original) An agent for preventing and/or treating an inflammatory disease, which inhibits the oligomerization of procaspase-1 by inhibiting the binding of NOD2 to procaspase-1.

13. (Original) The agent for preventing and/or treating an inflammatory disease according to claim 12, wherein the inflammatory disease is sepsis, inflammatory bowel disease, Crohn's disease or rheumatic disorder.

14. (Original) A reagent kit for use in the method according to claim 5, comprising at least one selected from NOD2, a polynucleotide encoding NOD2, a vector comprising the polynucleotide and a transformant comprising the vector; and at least one selected from procaspase-1, a polynucleotide encoding procaspase-1, a vector comprising the polynucleotide and a transformant comprising the vector.

15. (Original) A method of identifying a compound that inhibits the binding of NOD2 to a procaspase-1 variant which is a protein shown by the amino acid sequence as set forth in SEQ ID NO: 4 in the Sequencing Listing but has a substitution of the position at 285 of the amino acid sequence with alanine, comprising contacting NOD2 and/or the variant with a compound under conditions that allow for the binding of NOD2 to the variant, employing a system using a signal and/or a marker capable of detecting the binding of NOD2 to the variant, and detecting the presence or absence and/or the change of the signal and/or the marker to determine whether the compound inhibits the binding of NOD2 to the variant.

16. (New) The method of preventing and/or treating an inflammatory disease according to claim 3, wherein the inflammatory disease is sepsis, inflammatory bowel disease, Crohn's disease or rheumatic disorder.

17. (New) An agent for preventing and/or treating an inflammatory disease, comprising the agent according to claim 7.

18. (New) The agent for preventing and/or treating an inflammatory disease according to claim 9, wherein the inflammatory disease is sepsis, inflammatory bowel disease, Crohn's disease or rheumatic disorder.